Addition Therapeutics vs Genentech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Emerged from stealth with $100M (Dec 2025) backed by Gates Foundation, SR One, Abingworth. PRINT LNP platform integrates RNA at specific genomic loci — potentially re-dosable gene therapy for rare and chronic diseases.
About
Addition Therapeutics emerged from stealth in December 2025 with $100 million in financing backed by the Gates Foundation, SR One, and Abingworth, developing PRINT — a platform using lipid nanoparticles (LNPs) to deliver RNA and enzyme payloads that integrate therapeutic sequences at specific genomic loci. Unlike traditional AAV gene therapy (which requires viral vectors and can only be dosed once due to immune response), PRINT's non-viral approach is potentially re-dosable, opening gene therapy to chronic diseases beyond rare genetic disorders.
Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.
About
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Addition Therapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.